Search results
- (-) Remove Pipeline filter Pipeline
AXO–LENTI–PD (Axovant)
AXO–LENTI–PD
Gene-based treatment for Parkinson's disease
Status: Phase I/IIa study in preparation
SAR 422459 (Sanofi)
SAR422459
Gene therapy for Stargardt disease
Licensed to Sanofi: Phase II ongoing
OXB-202
OXB-202
Gene-based treatment for corneal graft rejection
Status: Phase I/II study in preparation
OXB–302
OXB-302
Gene-based immunotherapy targeting a range of cancers
Status: Pre–Clinical complete
OXB–201
OXB-201
Gene therapy for wet age-related macular degeneration
Status: Phase I trial complete
SAR 421869 (Sanofi)
SAR 421869
Gene therapy for Usher syndrome type 1B
Licensed to Sanofi: Phase I/IIa trial ongoing
LV305 (Immune Design)
LV305
This is a partner's product, where Oxford Biomedica provide process development and bioprocessing.